12:00 AM
 | 
Oct 08, 2012
 |  BioCentury  |  Emerging Company Profile

Fedora: Silver bullet against bugs

Fedora aims single bullet against beta lactamases for antibiotic resistance

Fedora Pharmaceuticals Inc. aims to head off bacterial growth with beta lactamase inhibitors that are effective against all classes of the antibiotic resistance-conferring enzyme. The Canadian startup hopes to advance one of its lead compounds into preclinical development by year end.

Beta lactamases are a diverse group of bacterial enzymes that degrade a variety of widely used antibiotics. The enzymes fall into four major classes - A, B, C and D - that vary considerably in their structure and biochemical characteristics, making it difficult to find a universally effective inhibitor.

The genes that encode beta lactamases readily spread between bacterial pathogens, leading to multiple drug resistance in many community- and hospital-acquired bacterial infections.

Four co-formulations of antibiotics with beta lactamase inhibitors are on the market and nearly a dozen more are in industry's pipeline, but the spread of beta lactamase variants has diminished the utility of existing inhibitors.

"The major difficulty is the evolution...

Read the full 760 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >